These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. The clinicopathological comparison among nodal cases of idiopathic multicentric Castleman disease with and without TAFRO syndrome. Kurose N; Futatsuya C; Mizutani KI; Kumagai M; Shioya A; Guo X; Aikawa A; Nakada S; Fujimoto S; Kawabata H; Masaki Y; Takai K; Aoki S; Kojima M; Nakamura S; Yamada S Hum Pathol; 2018 Jul; 77():130-138. PubMed ID: 29684500 [TBL] [Abstract][Full Text] [Related]
24. [Not Available]. Bertinchamp R; Terriou L Rev Med Interne; 2022 Dec; 43(10S1):10S4-10S9. PubMed ID: 36657941 [TBL] [Abstract][Full Text] [Related]
25. Utility of renal biopsy in differentiating idiopathic multicentric Castleman disease from IgG4-related disease. Kawanishi M; Kamei F; Sonoda H; Oba M; Fukunaga S; Egawa M; Koyama T; Sato Y; Tanabe K; Ito T CEN Case Rep; 2023 May; 12(2):242-248. PubMed ID: 36414812 [TBL] [Abstract][Full Text] [Related]
27. The French paediatric cohort of Castleman disease: a retrospective report of 23 patients. Borocco C; Ballot-Schmit C; Ackermann O; Aladjidi N; Delaleu J; Giacobbi-Milet V; Jannier S; Jeziorski E; Maurier F; Perel Y; Piguet C; Oksenhendler E; Koné-Paut I; Galeotti C Orphanet J Rare Dis; 2020 Apr; 15(1):95. PubMed ID: 32303241 [TBL] [Abstract][Full Text] [Related]
28. Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease. Fajgenbaum DC Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):318-325. PubMed ID: 30504327 [TBL] [Abstract][Full Text] [Related]
29. Clinical characteristics and outcomes of Castleman disease: a multicenter Consortium study of 428 patients with 15-year follow-up. Liu W; Cai Q; Yu T; Strati P; Hagemeister FB; Zhai Q; Zhang M; Li L; Fang X; Li J; Sun R; Zhang S; Yang H; Wang Z; Qian W; Iwaki N; Sato Y; Oksenhendler E; Xu-Monette ZY; Young KH; Yu L Am J Cancer Res; 2022; 12(9):4227-4240. PubMed ID: 36225639 [TBL] [Abstract][Full Text] [Related]
30. A Review of Genetic Abnormalities in Unicentric and Multicentric Castleman Disease. Butzmann A; Kumar J; Sridhar K; Gollapudi S; Ohgami RS Biology (Basel); 2021 Mar; 10(4):. PubMed ID: 33804823 [TBL] [Abstract][Full Text] [Related]
31. Comprehensive analysis of 65 patients with Castleman disease in a single center in China. Wang XQ; Zhong NN; Sun Q; Yan SC; Xu GC; Wang YG; Peng LW; Liu B; Bu LL Sci Rep; 2022 May; 12(1):8694. PubMed ID: 35610300 [TBL] [Abstract][Full Text] [Related]
32. Is TAFRO syndrome a subtype of idiopathic multicentric Castleman disease? Fujimoto S; Sakai T; Kawabata H; Kurose N; Yamada S; Takai K; Aoki S; Kuroda J; Ide M; Setoguchi K; Tsukamoto N; Iwao-Kawanami H; Kawanami T; Mizuta S; Fukushima T; Masaki Y Am J Hematol; 2019 Sep; 94(9):975-983. PubMed ID: 31222819 [TBL] [Abstract][Full Text] [Related]
33. The full spectrum of Castleman disease: 273 patients studied over 20 years. Oksenhendler E; Boutboul D; Fajgenbaum D; Mirouse A; Fieschi C; Malphettes M; Vercellino L; Meignin V; Gérard L; Galicier L Br J Haematol; 2018 Jan; 180(2):206-216. PubMed ID: 29143319 [TBL] [Abstract][Full Text] [Related]
34. ADA2 Deficiency Mimicking Idiopathic Multicentric Castleman Disease. Van Nieuwenhove E; Humblet-Baron S; Van Eyck L; De Somer L; Dooley J; Tousseyn T; Hershfield M; Liston A; Wouters C Pediatrics; 2018 Sep; 142(3):. PubMed ID: 30139808 [TBL] [Abstract][Full Text] [Related]
35. A Novel Predictive Model for Idiopathic Multicentric Castleman Disease: The International Castleman Disease Consortium Study. Yu L; Shi M; Cai Q; Strati P; Hagemeister F; Zhai Q; Li L; Fang X; Li J; Sun R; Zhang S; Yang H; Wang Z; Qian W; Iwaki N; Sato Y; Zhang L; Li J; Oksenhendler E; Xu-Monette ZY; Young KH Oncologist; 2020 Nov; 25(11):963-973. PubMed ID: 32852137 [TBL] [Abstract][Full Text] [Related]
36. Castleman disease and TAFRO syndrome: To improve the diagnostic consciousness is the key. Zhou QY World J Clin Cases; 2022 Feb; 10(5):1536-1547. PubMed ID: 35211591 [TBL] [Abstract][Full Text] [Related]
38. A benefit and the prospects of IL-6 inhibitors in idiopathic multicentric Castleman's disease. Koga T; Sumiyoshi R; Kawakami A; Yoshizaki K Mod Rheumatol; 2019 Mar; 29(2):302-305. PubMed ID: 30285516 [TBL] [Abstract][Full Text] [Related]
39. Clinical features and treatment outcomes of Castleman disease in children: a retrospective cohort in China. Hu S; Li Z; Wang H; Chen L; Ma Y; Zhu X; Li J; Dong R; Yao W; Dong C; Zhang H; Li K; Dong K; Zhai X Eur J Pediatr; 2023 Dec; 182(12):5519-5530. PubMed ID: 37782352 [TBL] [Abstract][Full Text] [Related]
40. Unicentric Castleman disease: A case report of an atypical presentation and successful management. Muhammad T; Alkheder A; Mazloum A; Almooay A; Naziha L; Shaheen M Int J Surg Case Rep; 2024 May; 118():109688. PubMed ID: 38669805 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]